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alive. Median serum CRP values were 23.5 (0.2-122.6) mg/l and 3.72 
(0.1-82.8) mg/l respectively (p=0.029). No correlation between CRP 
and pathologic stage of disease was found. Pretreatment Cyfra 21-1 
exceeded 3.3 ng/ml in 6/9 pts who died and 7/30 pts who were alive. 
Median Cyfra 21-1 concentrations were 5.29 (2.5-14.5) ng/ml and 1.92 
(0.7-6.2) respectively (p=0.0003). This difference was also signiﬁcant 
if only stage I and II pts were taken into analysis. 
Conclusion: Cyfra 21-1 and CRP are prognostic indicators in NSCLC 
patients treated by surgery and their inﬂuence on survival is probably 
partly independent from pathologic stage of disease. 
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Background: Intraoperative pleural lavage cytology (PLC) in patients 
with early stage of non-small cell lung cancer (NSCLCs) has been 
considered as possible aids to assess prognosis of lung cancers and was 
reported to be useful in detecting sub-clinical pleural dissemination, lo-
cal and systemic recurrence. Many studies revealed that only pre-opera-
tive PLC is necessary. We conduct a prospective study to explore any 
possible association of pre- and post-operative PCL and lymph node 
recurrence and the potential usefulness of post-operative PCL.
Methods: From December 2004 to December 2006, PLC was per-
formed before and after any manipulation or resection of the lung in 
24 consecutive patients, who had no macroscopic pleural effusion, 
dissemination, or diffuse adhesion, and who subsequently underwent 
curative resection for NSCLCs. The operations were performed by only 
one surgeon and the results of PLC with reference to clinicopathologic 
characteristics were evaluated and reported by only one pathologist. 
Tumor recurrence (local and systemic) was analyzed.
PLC consisted of cytological analysis of 50 mL of saline irrigated over 
the lung surface immediately after thoracotomy and after complete 
curative resection with radical mediastinal lymph node dissection.
Results: Nine (38%) of 24 patients had positive cytological ﬁndings. 
Positive cytological ﬁndings were observed more frequently in patients 
with adenocarcinoma, pleural involvement of the tumor and male 
gender.
Five (55%) of 9 patients had positive cytology in pre-operative PLC, 
3 (33%) in post-operative and 1 (11%) in both pre- and post-operative 
PLC. Exact McNemar signiﬁcance probability test showed no associa-
tion between pre- and post-operative cytological status (p= 0.727).
The risk of lymph nodes recurrence after 3 month of curative surgery 
in patients with negative and positive pre-operative PLC was 5.6% 
and 33.33% respectively (risk ratio = 6, 95%CI = 2 to 8, p = 0.143). In 
patients with both negative pre- and post-operative cytology, negative 
pre-operative but positive post-operative, positive pre-operative but 
negative post-operative, and positive both pre-and post-operative were 
6.7%, 0%, 20.0% and 100% respectively (p=0.123).
Conclusions: No relationship between cytological status of pleural 
lavage ﬂuid pre-operatively and post-operatively was detected. The 
study showed that if malignant cells were found in pre-operative PLC, 
the risk of lymph node recurrence in 3 months increased by 6 times, 
and maximum risk occurred when the malignant cells was found in 
both pre- and post-operative PLC. However, the increased risk was not 
statistically signiﬁcant because of the lack of statistical power due to 
small study size. If sample size were increased it may reveal that PLC 
may also be required at the time of curative resection for non-small cell 
lung cancer in order to estimate the risk of lymph node recurrence.
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Background: The primary aim of this trial was response. In both the 
control arm and in the genotypic arm with low tumor ERCC1 mRNA 
levels, p received docetaxel(doc)/cis; in the genotypic arm with high tu-
mor ERCC1 mRNA levels, p received doc/gemcitabine. Response was 
signiﬁcantly higher in the genotypic arms. We examined 324 p for ge-
netic markers that could inﬂuence response, including ERCC1 118 C/T, 
ERCC1 C8092A, XRCC3 241 (Thr to Met), Aurora A 91 T>A, Aurora 
A 169G>A, a SNP within intron 7 of the TGFBR1 gene (Int7G24A), 
and an in-frame germline deletion (TGFBR1*6A). Methylation of 14-
3-3 sigma and CHFR were also analyzed. 
Methods: DNA from peripheral lymphocytes was used for genotyp-
ing (Taqman assay) and methylation-speciﬁc PCR was used for 14-3-3 
sigma and CHFR in pretreatment serum DNA. 
Results: There were no differences in clinical characteristics among 
the different SNP types, except that p with Aurora A 91 AA had higher 
tumor ERCC1 mRNA levels (P=0.005). No relationship was found 
between ERCC1 SNPs and tumor ERCC1 mRNA levels. A strong 
correlation was found between the Int7G24A and XRCC3 241 SNPs 
(P=0.03). The Int7G24A GA type had a higher odds ratio (OR) of 
response (OR 2.32) than the AA type (OR 3.15) (P=0.02). XRCC3 241 
MetMet had a lower probability of response (OR 0.23) (P=0.04). No 
other differences in response were observed according to any of the 
other SNPs or methylation. In the multivariate model, the best response 
was observed in p with performance status (PS) 0, low ERCC1 levels, 
and XRCC3 241 SNP (Table). 
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Conclusions: Further research is warranted to deﬁne the role of theT-
GFBR1 Int7G24A gene in customized treatments.
 N OR (95% CI) P
ARM 
Control 126 0.57 (0.34-0.93) 0.02
Low ERCC1 114 1 ref  
High ERCC1 84 0.80 (0.46-1.39) 0.54
PS 
o 124 1 ref  
1 200 0.55 (0.35-0.85) 0.004
XRCC3 
ThrThr 138 0.82 (0.51-1.32) 0.42
ThrMet 155 1 ref  
MetMet 31  0.30 (0.12-0.72) 0.007
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Plasma lactate dehydrogenase (LDH) is a biochemical parameter sup-
posed to get elevated in lung cancer, especially in advanced tumors. 
LDH is an important enzyme which catalyses lactate formation from 
pyruvate in anaerobic metabolism. It is called to be a non-speciﬁc 
indicator of dying tumor cells by reﬂecting their rapid turnover. In our 
study, we aimed to show that plasma LDH levels are found to be high 
in lung cancer and LDH can reﬂect the stage and prognosis of tumor. 
We detected 40 patients with new diagnosis of non small cell lung 
cancer. We chose a control group of 40 patients with chronic obstruc-
tive pulmonary disease (COPD). In lung cancer group, we chose the 
patients without history of COPD; also COPD patients elected for con-
trol group didn’t have diagnosis of lung cancer. The history of smoking 
wasn’t thought to affect the results of our study as it was an intersection 
of both groups. Gender and age were found to be statistically similar 
for each group. We accepted the normal plasma level of LDH between 
240-480 U / l.
The mean level of LDH was 606,5 U / l in lung cancer group when it 
was found as 387,3 U / l in control group which was statistically sig-
niﬁcant (p=0,002). In control group, we found 7 patients having a high 
value of LDH (15 %); it seemed to be high in 20 patients of lung cancer 
group (%50).
Afterwards, NSCLC group was examined if LDH levels differed ac-
cording to stage and tumoral type. By using TNM staging, 26 of 40 
patients were found to be in stage IV, 7 in stage IIIb and 7 in stage 
IIIa. Plasma level of LDH was high in 14 of 26 stage IV patients, 3 in 
7 stage IIIb and 3 in 7 stage IIIa. We examined mean LDH levels ac-
cording to stages of tumors: 453.8 in stage IIIa, 508.3 in stage IIIb, and 
684.2 in stage IV, which shows that LDH is high in advanced NSCLC. 
However, LDH levels weren’t found statistically signiﬁcant according 
to stages. We think that the heterogen distribution of tumor stages can 
be the reason of it.
There were 15 squamous cell, 15 adenocarcinoma and 10 uncertain 
histopathological type of NSCLC in lung cancer group. LDH was high 
in 6 of 15 squamous cell, in 8 of 15 adenocarcinoma and in 6 of other 
10 NSCLC. The mean LDH level was 504.1 in squamous cell, 642.5 in 
adenocarcinoma and 673 in other NSCLC; we can see that LDH levels 
are higher in adenocarcinoma. This data achieved according to tumor 
types wasn’t found statistically signiﬁcant; the limited number of the 
universe can explain this result.
The results of our study supports that plasma LDH levels are higher 
in patients with lung cancer. Although LDH levels were found to be 
high in advanced NSCLC and in adenocarcinoma,but statistically not 
signiﬁcant, more advanced studies with a high number and homogen 
distribution of patients should have done to conﬁrm these results. 
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Background: There are some data supporting differences by sex 
in lung cancer. So we undertook a retrospective analysis of clinico-
pathologic and genetic features in women (W) with advanced NSCLC 
participating in ﬁrst-line chemotherapy (CT) SLCG trials. 
Methods: Data on age, histology, PS, CT schedule, XRCC3 (DNA 
repair capacity gene) single nucleotide polymorphisms (SNPs) as-
sessment in DNA from peripheral blood lymphocytes, CT outcomes, 
survival and disease free-survival were obtained. 
Results: 1125 p included in 4 SLCG trials from 2001 to 2005 treated 
with CT based on CDDP/GEM, CDDP/DOC or DOC/GEM were 
analysed. 167 p (14.9%) were W. W were signiﬁcantly younger than 
men (M) (median, 57 yrs vs 61 yrs, P<0.0001). Adenocarcinoma 
subtype was more predominant in W than in men (76% vs 47%, 
P<0.0001). There were not signiﬁcant differences by sex considering 
PS (0/1)(P<0.85), stage (IIIB/IV)(P<0.18) or overall response rate 
(P<0.45). Median time to progression (TTP) was 6.8 months (m) vs 5.3 
m (P<0.009) in favour of W. Median overall survival (OS) was 11.4 
m for W vs 9.1 m for M (P<0.001). No differences were found in the 
subgroup of patients receiving DOC/GEM probably due to the small 
number of patients. XRCC3 SNPs were distributed similarly between 
sexes. SNPs genotype of both XRCC3 241Met/Met and Thr/Met 
correlates with better survival in W vs M (P<0.05 and P<0.008). In a 
multivariate analysis, sex was an independent predictive marker for 
both OS (HR 1.5, 95% CI 1.2-1.9, P<0.0001) and TTP (HR 1.4, 95% 
CI 1.1-1.7, P<0.001), others independent variables found were PS, age, 
type of CT, but not XRCC3 241 genotype.
Conclusions: In this retrospective analysis of four SLCG trials, women 
with NSCLC were found to have better prognosis than men. Results 
